GLP-1 Weight-Loss Drugs Market to Reach $100 Billion by 2027

GLP-1 Drug Market

Market to hit $100 billion by 2027

Oral versions arriving in 2026 will cut prices

Growth driven by competition and wider access

Stock video by Tima Miroshnichenko via Pexels

Mar 21, 2026

GLP-1 Weight-Loss Drugs Market to Reach $100 Billion by 2027

According to an analysis from ING, obesity and Type 2 diabetes represent significant societal and economic challenges. The prevalence of obesity among adults in the United States rose from just over 10 percent in 1975 to 43 percent in 2022. Globally, there are now more individuals classified as overweight than malnourished. Medications known as GLP-1s have proven effective for treating diabetes and facilitating weight reduction, with users often losing between 12 and 22 percent of their body weight.

These health conditions are associated with costly complications, including cardiovascular diseases and joint problems, and can reduce workforce participation and productivity. Approximately 90 percent of diabetes cases are Type 2, which is influenced by genetics, lifestyle, and weight. The high costs of managing diabetes and its complications strengthen the rationale for using GLP-1 medications.

The market for these drugs has expanded rapidly since their introduction. The global market was valued at approximately $70 billion last year. An estimated one in five adults in the U.S. has tried a weight-loss drug, with current usage around 12 percent. In Europe and the United Kingdom, at least 2 percent of adults, equating to roughly nine to ten million people, are currently using them. Adoption has been faster in wealthier nations such as the UK and Nordic countries, while Central and Eastern Europe show slower uptake despite higher obesity rates. Users are more likely to be older and female, and include both those paying out-of-pocket and those receiving treatment for diabetes.

However, studies indicate about half of users discontinue the drugs within one year due to cost, side effects, or achieving a target weight. This pattern of intermittent use can temporarily affect demand for certain food and beverage products.

Market Evolution and Future Scenarios

Several factors will influence the future market size for GLP-1 drugs. The GLP-1 market will become predominantly oral in the US in 2026 and in Europe in 2027, which could lower prices by up to half and increase usage. Increased competition from new drug launches and potential government reimbursement for more patients could further boost demand. Given that revenues for many weight-loss drugs doubled last year, and considering that only an estimated 40 percent of people with diabetes receive treatment, the market is projected to grow by 20 percent over the next two years, reaching about $100 billion by the end of 2027.

A key unresolved question is the sustainability of weight loss achieved with these drugs. Current research suggests patients tend to regain weight after stopping treatment, though newer therapies are still in development.

Limited Near-Term Impact on Food Demand

The immediate impact of GLP-1 usage on overall food and beverage demand is expected to be minimal. While users may reduce calorie intake by 15 to 20 percent, the current low usage rate translates to only about a 0.25 percent reduction in total calorie demand across the EU and UK. Consequently, a significant negative effect on demand is not anticipated for 2026 and 2027.

Nevertheless, certain product categories like savory snacks, candy, chocolate, and alcoholic beverages appear more exposed to reduced consumption. Some companies are already adapting; for instance, bakery company Grupo Bimbo has increased focus on reformulation and portion control, while The Magnum Ice Cream Company noted a consumer shift toward fewer but more premium products. These changes have also led some ingredient suppliers, such as sugar traders, to adjust consumption forecasts for North America and Europe.

Long-Term Uncertainty and Corporate Adaptation

The longer-term impact on the food and beverage market remains uncertain, hinging on two main factors: the duration of the drugs' effect on weight and calorie intake, and the concentration of any consumption shifts between product categories. In a transformative scenario, increased GLP-1 use could reduce total calorie intake by 2.5 to 3.5 percent by 2030, with higher reductions in the most affected categories. For context, many users reduce daily intake by 700 calories or more. An overhyped scenario would see limited impact due to restricted drug usage.

The most likely outcome varies by country, influenced by differing public health systems, budget constraints, and disease prevalence. Some national health authorities are cautiously expanding access, but costs remain a concern. Unlike sudden supply chain disruptions, food and beverage companies have time to prepare for increasing drug adoption.

Analysts note that while GLP-1s address individual health problems, they do not resolve the systemic issues in a food system oriented toward convenience and overconsumption. A more profound impact on demand would require policymakers to implement additional measures like taxation, subsidies, and marketing restrictions, which have not been widely adopted in Europe. For manufacturers, a gradual adaptation strategy is likely sufficient for the immediate future, though planning for more extreme scenarios is advised.

This report provides a comprehensive view of the prophylactic medicaments containing insulin industry in Europe, tracking demand, supply, and trade flows across the regional value chain. It explains how demand across key channels and end-use segments shapes consumption patterns, while also mapping the role of input availability, production efficiency, and regulatory standards on supply.

Beyond headline metrics, the study benchmarks prices, margins, and trade routes so you can see where value is created and how it moves between exporters and importers within Europe. The analysis is designed to support strategic planning, market entry, portfolio prioritization, and risk management in the prophylactic medicaments containing insulin landscape in Europe.

Quick navigation

Key findings
Report scope
Product coverage
Country coverage
Methodology
Forecasts to 2035
Price analysis
Market participants
Country profiles
How to use this report
FAQ

Key findings

Regional demand is shaped by both household and industrial usage, with trade flows linking supply hubs to import-reliant countries.
Pricing dynamics reflect unit values, freight costs, exchange rates, and regulatory shifts that affect sourcing decisions.
Supply depends on input availability and production efficiency, creating distinct cost curves across Europe.
Market concentration varies by country, creating different competitive landscapes and entry barriers.
The 2035 outlook highlights where capacity investment and demand growth are most aligned within the region.

Report scope

The report combines market sizing with trade intelligence and price analytics for Europe. It covers both historical performance and the forward outlook to 2035, allowing you to compare cycles, structural shifts, and policy impacts across countries and sub-regions.

Market size and growth in value and volume terms
Consumption structure by end-use segments and countries
Production capacity, output, and cost dynamics
Regional trade flows, exporters, importers, and balances
Price benchmarks, unit values, and margin signals
Competitive context and market entry conditions

Product coverage

Prodcom 21201260 - Medicaments containing insulin but not antibiotics, for therapeutic or prophylactic uses, put up in measured doses or for retail sale

Country coverage

Country profiles and benchmarks

For the regional report, country profiles provide a consistent view of market size, trade balance, prices, and per-capita indicators across Europe. The profiles highlight the largest consuming and producing markets and allow direct benchmarking across peers.

Methodology

The analysis is built on a multi-source framework that combines official statistics, trade records, company disclosures, and expert validation. Data are standardized, reconciled, and cross-checked to ensure consistency across time series.

International trade data (exports, imports, and mirror statistics)
National production and consumption statistics
Company-level information from financial filings and public releases
Price series and unit value benchmarks
Analyst review, outlier checks, and time-series validation

All data are normalized to a common product definition and mapped to a consistent set of codes. This ensures that comparisons across time are aligned and actionable.

Forecasts to 2035

The forecast horizon extends to 2035 and is based on a structured model that links prophylactic medicaments containing insulin demand and supply to macroeconomic indicators, trade patterns, and sector-specific drivers. The model captures both cyclical and structural factors and reflects known policy and technology shifts within Europe.

Historical baseline: 2012-2025
Forecast horizon: 2026-2035
Scenario-based sensitivity to income growth, substitution, and regulation
Capacity and investment outlook for major producing countries

Each country projection is built from its own historical pattern and the regional context, allowing the report to show where growth is concentrated and where risks are elevated.

Price analysis and trade dynamics

Prices are analyzed in detail, including export and import unit values, regional spreads, and changes in trade costs. The report highlights how seasonality, freight rates, exchange rates, and supply disruptions influence pricing and margins.

Price benchmarks by country and sub-region
Export and import unit value trends
Seasonality and calendar effects in trade flows
Price outlook to 2035 under baseline assumptions

Profiles of market participants

Key producers, exporters, and distributors are profiled with a focus on their operational scale, geographic footprint, product mix, and market positioning. This helps identify competitive pressure points, partnership opportunities, and routes to differentiation.

Business focus and production capabilities
Geographic reach and distribution networks
Cost structure and pricing strategy indicators
Compliance, certification, and sustainability context

How to use this report

Quantify regional demand and identify the most attractive country markets
Evaluate export opportunities and prioritize target destinations
Track price dynamics and protect margins
Benchmark performance against regional competitors
Build evidence-based forecasts for investment decisions

This report is designed for manufacturers, distributors, importers, wholesalers, investors, and advisors who need a clear, data-driven picture of prophylactic medicaments containing insulin dynamics in Europe.

FAQ

What is included in the prophylactic medicaments containing insulin market in Europe?

The market size aggregates consumption and trade data at country and sub-regional levels, presented in both value and volume terms.

How are the forecasts to 2035 built?

The projections combine historical trends with macroeconomic indicators, trade dynamics, and sector-specific drivers.

Does the report cover prices and margins?

Yes, it includes export and import unit values, regional spreads, and a pricing outlook to 2035.

Which countries are profiled in detail?

The report provides profiles for the largest consuming and producing countries in Europe.

Can this report support market entry decisions?

Yes, it highlights demand hotspots, trade routes, pricing trends, and competitive context.

1. INTRODUCTION

Making Data-Driven Decisions to Grow Your Business
1. REPORT DESCRIPTION
2. RESEARCH METHODOLOGY AND THE AI PLATFORM
3. DATA-DRIVEN DECISIONS FOR YOUR BUSINESS
4. GLOSSARY AND SPECIFIC TERMS
2. EXECUTIVE SUMMARY

A Quick Overview of Market Performance
1. KEY FINDINGS
2. MARKET TRENDS This Chapter is Available Only for the Professional EditionPRO
3. MARKET OVERVIEW

Understanding the Current State of The Market and its Prospects
1. MARKET SIZE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
2. CONSUMPTION BY COUNTRY: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
3. MARKET FORECAST TO 2035
4. MOST PROMISING PRODUCTS FOR DIVERSIFICATION

Finding New Products to Diversify Your Business
- This Chapter is Available Only for the Professional EditionPRO
1. TOP PRODUCTS TO DIVERSIFY YOUR BUSINESS
2. BEST-SELLING PRODUCTS
3. MOST CONSUMED PRODUCTS
4. MOST TRADED PRODUCTS
5. MOST PROFITABLE PRODUCTS FOR EXPORT
5. MOST PROMISING SUPPLYING COUNTRIES

Choosing the Best Countries to Establish Your Sustainable Supply Chain
- This Chapter is Available Only for the Professional EditionPRO
1. TOP COUNTRIES TO SOURCE YOUR PRODUCT
2. TOP PRODUCING COUNTRIES
3. TOP EXPORTING COUNTRIES
4. LOW-COST EXPORTING COUNTRIES
6. MOST PROMISING OVERSEAS MARKETS

Choosing the Best Countries to Boost Your Export
- This Chapter is Available Only for the Professional EditionPRO
1. TOP OVERSEAS MARKETS FOR EXPORTING YOUR PRODUCT
2. TOP CONSUMING MARKETS
3. UNSATURATED MARKETS
4. TOP IMPORTING MARKETS
5. MOST PROFITABLE MARKETS
7. PRODUCTION

The Latest Trends and Insights into The Industry
1. PRODUCTION VOLUME AND VALUE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
2. PRODUCTION BY COUNTRY: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
8. IMPORTS

The Largest Import Supplying Countries
1. IMPORTS: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
2. IMPORTS BY COUNTRY: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
3. IMPORT PRICES BY COUNTRY: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
9. EXPORTS

The Largest Destinations for Exports
1. EXPORTS: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
2. EXPORTS BY COUNTRY: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
3. EXPORT PRICES BY COUNTRY: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
10. PROFILES OF MAJOR PRODUCERS

The Largest Producers on The Market and Their Profiles
- This Chapter is Available Only for the Professional EditionPRO
11. COUNTRY PROFILES

The Largest Markets And Their Profiles
This Chapter is Available Only for the Professional Edition PRO
1. 11.1
  Albania
  - Market Size
  - Production
  - Imports
  - Exports
2. 11.2
  Andorra
  - Market Size
  - Production
  - Imports
  - Exports
3. 11.3
  Austria
  - Market Size
  - Production
  - Imports
  - Exports
4. 11.4
  Belarus
  - Market Size
  - Production
  - Imports
  - Exports
5. 11.5
  Belgium
  - Market Size
  - Production
  - Imports
  - Exports
6. 11.6
  Bosnia and Herzegovina
  - Market Size
  - Production
  - Imports
  - Exports
7. 11.7
  Bulgaria
  - Market Size
  - Production
  - Imports
  - Exports
8. 11.8
  Croatia
  - Market Size
  - Production
  - Imports
  - Exports
9. 11.9
  Czech Republic
  - Market Size
  - Production
  - Imports
  - Exports
10. 11.10
  Denmark
  - Market Size
  - Production
  - Imports
  - Exports
11. 11.11
  Estonia
  - Market Size
  - Production
  - Imports
  - Exports
12. 11.12
  Faroe Islands
  - Market Size
  - Production
  - Imports
  - Exports
13. 11.13
  Finland
  - Market Size
  - Production
  - Imports
  - Exports
14. 11.14
  France
  - Market Size
  - Production
  - Imports
  - Exports
15. 11.15
  Germany
  - Market Size
  - Production
  - Imports
  - Exports
16. 11.16
  Gibraltar
  - Market Size
  - Production
  - Imports
  - Exports
17. 11.17
  Greece
  - Market Size
  - Production
  - Imports
  - Exports
18. 11.18
  Holy See
  - Market Size
  - Production
  - Imports
  - Exports
19. 11.19
  Hungary
  - Market Size
  - Production
  - Imports
  - Exports
20. 11.20
  Iceland
  - Market Size
  - Production
  - Imports
  - Exports
21. 11.21
  Ireland
  - Market Size
  - Production
  - Imports
  - Exports
22. 11.22
  Italy
  - Market Size
  - Production
  - Imports
  - Exports
23. 11.23
  Latvia
  - Market Size
  - Production
  - Imports
  - Exports
24. 11.24
  Lithuania
  - Market Size
  - Production
  - Imports
  - Exports
25. 11.25
  Luxembourg
  - Market Size
  - Production
  - Imports
  - Exports
26. 11.26
  North Macedonia
  - Market Size
  - Production
  - Imports
  - Exports
27. 11.27
  Malta
  - Market Size
  - Production
  - Imports
  - Exports
28. 11.28
  Moldova
  - Market Size
  - Production
  - Imports
  - Exports
29. 11.29
  Montenegro
  - Market Size
  - Production
  - Imports
  - Exports
30. 11.30
  Netherlands
  - Market Size
  - Production
  - Imports
  - Exports
31. 11.31
  Norway
  - Market Size
  - Production
  - Imports
  - Exports
32. 11.32
  Poland
  - Market Size
  - Production
  - Imports
  - Exports
33. 11.33
  Portugal
  - Market Size
  - Production
  - Imports
  - Exports
34. 11.34
  Romania
  - Market Size
  - Production
  - Imports
  - Exports
35. 11.35
  Russia
  - Market Size
  - Production
  - Imports
  - Exports
36. 11.36
  San Marino
  - Market Size
  - Production
  - Imports
  - Exports
37. 11.37
  Serbia
  - Market Size
  - Production
  - Imports
  - Exports
38. 11.38
  Slovakia
  - Market Size
  - Production
  - Imports
  - Exports
39. 11.39
  Slovenia
  - Market Size
  - Production
  - Imports
  - Exports
40. 11.40
  Spain
  - Market Size
  - Production
  - Imports
  - Exports
41. 11.41
  Sweden
  - Market Size
  - Production
  - Imports
  - Exports
42. 11.42
  Switzerland
  - Market Size
  - Production
  - Imports
  - Exports
43. 11.43
  Ukraine
  - Market Size
  - Production
  - Imports
  - Exports
44. 11.44
  United Kingdom
  - Market Size
  - Production
  - Imports
  - Exports
45. 11.45
  Liechtenstein
  - Market Size
  - Production
  - Imports
  - Exports
46. 11.46
  Isle of Man
  - Market Size
  - Production
  - Imports
  - Exports
47. 11.47
  Monaco
  - Market Size
  - Production
  - Imports
  - Exports
LIST OF TABLES
1. Key Findings In 2025
2. Market Volume, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
3. Market Value: Historical Data (2012–2025) and Forecast (2026–2035)
4. Per Capita Consumption, by Country, 2022–2025
5. Production, In Physical Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
6. Imports, In Physical Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
7. Imports, In Value Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
8. Import Prices, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
9. Exports, In Physical Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
10. Exports, In Value Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
11. Export Prices, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
LIST OF FIGURES
1. Market Volume, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
2. Market Value: Historical Data (2012–2025) and Forecast (2026–2035)
3. Consumption, by Country, 2025
4. Market Volume Forecast to 2035
5. Market Value Forecast to 2035
6. Market Size and Growth, By Product
7. Average Per Capita Consumption, By Product
8. Exports and Growth, By Product
9. Export Prices and Growth, By Product
10. Production Volume and Growth
11. Exports and Growth
12. Export Prices and Growth
13. Market Size and Growth
14. Per Capita Consumption
15. Imports and Growth
16. Import Prices
17. Production, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
18. Production, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
19. Production, by Country, 2025
20. Production, In Physical Terms, by Country: Historical Data (2012–2025) and Forecast (2026–2035)
21. Imports, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
22. Imports, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
23. Imports, In Physical Terms, By Country, 2025
24. Imports, In Physical Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
25. Imports, In Value Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
26. Import Prices, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
27. Exports, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
28. Exports, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
29. Exports, In Physical Terms, By Country, 2025
30. Exports, In Physical Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
31. Exports, In Value Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
32. Export Prices, By Country: Historical Data (2012–2025) and Forecast (2026–2035)

Recommended posts

B Group Invests $6.26M in Structure Therapeutics in Q4 2025

DAFNA Capital Boosts Biohaven Stake to $10.78M in Q4 2025

Novo Nordisk Stock Decline: Challenges and Valuation in 2026

Novo Nordisk Stock: Market Challenges vs. Long-Term Strengths in 2026